Our new, proprietary class of theranostics enable the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

Our Theranostic technology and approach has been featured in the following publications

Publications – 2016-present


Thakral P, Sen I, Das SS, Schultz MK, Kumari J, Virupakshappa CB, Malik D. Pb-203 VMT-α-NET Scintigraphy: A promising theranostics agent. Indian Journal of Nuclear Medicine; Submitted January 2023.

Li M, Baumhover NJ, Liu D, Cagle BS, Boschetti F, Paulin G, Lee D, Dai Z, Obot ER, Marks BM, Okeil I, Sagastume EA, Gabr M, Pigge FC, Johnson FL, Schultz MK. Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for 203Pb and 212Pb-Based Theranostics. Pharmaceutics, 2023, (15), 414

Nelson BJB, Wilson J, Michael K. Schultz MK, Andersson JD, Wuest F. High-yield cyclotron production of 203Pb using a sealed 205Tl solid target. Nuclear Medicine and Biology, 2023, (116-117), 108314

Mueller D, Herrmann H, Schultz MK, Solbach C, Kletting P, Ettrich T, and Prasad V. [203Pb]VMT-α-NET Scintigraphy of a patient with neuroendocrine tumor. Clinical Nuclear Medicine, 2023, (48), 54-55


Orcutt KD, Henry KE, Habjan C, Palmer K, Heimann J, Cupido JM, Gottumukkala V, Cissell DD, Lyon M, Hussein AI, Liu D, Li M, Johnson FL, & Schultz MK. Dosimetry of [212Pb]VMT01, a MC1R-targeted Alpha Therapeutic Compound, and Effect of Free 208Tl on Tissue Absorbed Doses. Molecules, 2022, (27), 5831.

Pouget J-P, Wuest F, Nelson B, Andersson J, Cheal S, Li M, Ianzini F, Ray S, Graves SE, Chouin N and Schultz MK. The Radiobiology of Targeted Alpha Therapy. Nuclear Medicine and Molecular Imaging, 2022 (4), 380-403.

Zhang S, Wang H, Ren S Ren, Chen Y, Liu D, Li, M, Sagastume E, and Chong HS. Synthesis and evaluation of Diaza-Crown Ether-Backboned chelator containing hydroxamate groups for Zr-89 chelation chemistry. Bioorganic and Medicinal Chemistry Letters, 2022, (72), 128847


Kunos CA, David A. Mankoff DA, Schultz MK, Graves SA, Pryma DA. Radiopharmaceutical Chemistry and Drug Development – What’s Changed? Seminars in Radiation Oncology, 2021, (31), 3-11

Varmazyad M, Modi MM, Kalen AL, Sarsour EH, Wagner B, Du J, Schultz MK, Buettner GR, Pigge FC, Goswami PC. N-alkyl Triphenylvinylpyridinium Conjugated Dihydroartemisinin Perturbs Mitochondrial Functions Resulting in Enhanced Cancer Versus Normal Cell Toxicity.

Free Radical Biology and Medicine, 2021, (165), 421-434

Li M, Liu D, Lee D, Cheng Y, Baumhover NJ, Marks BM, Sagastume EA, Ballas ZK, Johnson FL, Morris ZS, Schultz MK. Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma. Cancers, 2021, (13), 3676


Li M, Sagastume EA, Lee D, McAlister D, DeGraffenreid AJ, Olewine KR, Graves SA, Copping R, Mirzadeh S, Zimmerman BE, Larsen RH, Johnson FL, and Schultz MK. Pb-203/Pb-212 Theranostic Radiopharmaceuticals for Image-Guided Radionuclide Therapy for Cancer. Current Medicinal Chemistry, 2020 (27) 1-29.

Kloepping KC, Kraus AS, Hedlund DK, Gnade CM, Wagner BA, McCormick ML, Fath MA, Seol D, Lim TH, Buettner GR, Goswami PC, Pigge FC, Spitz DR, Schultz MK. Triphenylphosphonium Derivatives Disrupt Metabolism and Inhibit Melanoma Growth In Vivo when Delivered Via a Thermosensitive Hydrogel. PLoS One, 2020, 15(12): e0244540.

Falls-Hubert KC, Butler A, Gui K, Anderson M, Li M, Stolwijk JM, Rodman III SN, Solst SR, Tomanek-Chalkley A, Searby CC, Sheffield VC, Sandfort V, Schmidt H, McCormick M, Wels BR, Allen BG, Buettner GR, Schultz MK, Spitz DR. Disulfiram Causes Selective Hypoxic Cancer Cell Toxicity and Radio-Chemo-Sensitization Via Redox Cycling of Copper. Free Radical Biology and Medicine, 2020 (150) 1-11.


Li M, Lee D, Liu D, Quinn TP, Sagastume EA, Mott S, Gibsen-Corley KN, Johnson FL, Schultz MK. (2019) MAPK and HDAC Inhibitors Sensitize Malignant Melanoma to Alpha-particle Radiation Targeting Melanocortin Subtype 1 Receptor (MC1R). Molecular Pharmaceutics, 2019 (16) 3904-3915.

Vanneste M, Huang Q, Li M, Moose D, Zhao L, Stamnes M, Schultz MK, Wu M, Henry M. High Content Screening Identifies Monensin as an EMT-Selective Cytotoxic Compound. Scientific Reports, 2019 (9) 1200.


Menda Y, Madsen MT, O’Dorisio TM, Sunderland J, Watkins LG, Dillon JS, Mott SL, Schultz MK, Zamba GKD, Bushnell DL, O’Dorisio MS. 90Y- DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine, 2018 (59) 1692-1698.

Lee D, Li M, Bednarz B, Schultz MK. Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy. Radiation Research, 2018 (190) 236-247.

Ghai A, Singh B, Li M, Daniels TA, Coelho R, Orcutt K, Watkins GL, Norenberg JP, Cvet D, Schultz MK. Optimizing the Radiosynthesis of [68Ga]DOTA-MLN6907 Peptide Containing Three Disulfide Cyclization Bonds – A GCC Specific Chelate for Clinical Radiopharmaceuticals. Applied Radiation and Isotope, 2018 (140) 333-341.


Li M, Zhang X, Quinn TP, Lee D, Liu D, Kunkel F, Zimmerman BE, McAlister D, Olewine K, Menda Y, Mirzadeh S, Copping R, Sagastume, Johnson FL, Schultz MK. Production of High Specific Activity [203/212-Pb]DOTA-Conjugated Radiopharmaceuticals for Clinical Image-Guided Radionuclide Cancer Therapy Using an Automated Cassette-Based System. Applied Radiation and Isotopes, 2017 (127) 52-60.

May D, Nelson AN, Schultz MK. Quantitation of Lead-210 (Pb-210) Using Lead-203 (Pb-203) as a “Massless” Yield Tracer. Journal Environ Radioact, 2017 (171) 93-98.

Menda Y, O’Dorisio TM, Howe JR, Schultz MK, Dillon JS, Dick D, Watkins GL, Ginader T, Bushnell DL, Sunderland JJ, Zamba GKD, Graham M, O’Dorisio MS. Localization of Unknown Primary Site with [68Ga]DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor. Journal of Nuclear Medicine, 2017 (58) 1054-1057.

Schoenfeld JD, Sibenaller ZA, Cramer-Morales KL, Mapuskar KA, Wagner BA, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Furqan M, Berg DJ, Zhang J, Keech,J, Parekh KR, Bhatia S, Bodekar KL, Ahmann L, Vollstedt S, Brown H, Shanahan-Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Smith B, Greenlee JD, Howard MA, Monda V, Riley DP, Schultz MK, Domann FE, Cullen JJ, Buettner GR, Buatti, JM , Spitz DR, Allen BG. O2·- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cel,. 2017 (32) 268.


Reedy JL, Gabr MT, Hedlund DK, Pigge FC, Schultz MK Synthesis and Evaluation of Mitochondrial-Targeted triphenylvinylpyridine (TPVP) Derivatives for the Treatment of Metastatic Melanoma. Biococonjugate Chemistry, 2016 (27) 2424-2430

Schibler J, Tomanek-Chalkley AM, Reedy JL, Zhan F, Spitz DR, Schultz MK, Goel A Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma Cells. PLoS One, 2016 11(11): e0167323

Mueller D, Breeman WAP, Klette I, Gottschald A, Odparlik A, Baehre M, Tworowska I, Schultz MK (2016). Radiolabeling of DOTA-Like Conjugated Peptides with Generator-Produced 68Ga and Using NaCl Based Cationic Elution Method. Nature Protocols, 2016 (11) 1057–1066.

Want to know more about this new class of Theranostics?